A MULTICENTER, PROSPECTIVE, OBSERVATIONAL, NON-INTERVENTIONAL COHORT STUDY IN CHINESE SUBJECTS WITH HBeAg NEGATIVE CHRONIC HEPATITIS B (CHB) RECEIVING THERAPY WITH PEGINTERFERON ALFA
Phase of Trial: Phase IV
Latest Information Update: 18 Jul 2017
Price : $35 *
At a glance
- Drugs Peginterferon alfa-2a (Primary)
- Indications Hepatitis B
- Focus Therapeutic Use
- Sponsors Roche
- 13 Jul 2017 Status changed from active, no longer recruiting to completed.
- 03 Apr 2017 Planned End Date changed from 8 Apr 2017 to 25 Jun 2017.
- 03 Apr 2017 Planned primary completion date changed from 8 Apr 2017 to 25 Jun 2017.